
Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Muscarinic Acetylcholine Receptor M4 (CHRM4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 20 molecules. Out of which approximately 20 molecules are developed by Companies. The latest report GMDHC22094TDB - Muscarinic Acetylcholine Receptor M4 - Drugs In Development, 2022, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 12 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Schizophrenia, Alzheimer's Disease, Psychosis, Parkinson's Disease, Angelman Syndrome, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Neurology, Presbyopia, Rett Syndrome, Tuberous Sclerosis, Unspecified Neurologic Disorders, Unspecified Psychiatric Disorders and Unspecified Rare Disease.
Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 20 molecules. Out of which approximately 20 molecules are developed by Companies. The latest report GMDHC22094TDB - Muscarinic Acetylcholine Receptor M4 - Drugs In Development, 2022, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 3, 12 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Ophthalmology and Undisclosed which include indications Schizophrenia, Alzheimer's Disease, Psychosis, Parkinson's Disease, Angelman Syndrome, Cognitive Impairment Associated With Schizophrenia (CIAS), Drug-Induced Dyskinesia, Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Neurology, Presbyopia, Rett Syndrome, Tuberous Sclerosis, Unspecified Neurologic Disorders, Unspecified Psychiatric Disorders and Unspecified Rare Disease.
Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
74 Pages
- Introduction
- Global Markets Direct Report Coverage
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Overview
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Anavex Life Sciences Corp
- AstraZeneca Plc
- Cerevel Therapeutics Holdings Inc
- Karuna Therapeutics Inc
- Lan Sheng Biomedicine Suzhou Co Ltd
- Lenz Therapeutics LLC
- MapLight therapeutics Inc
- Neumora Therapeutics Inc
- Neurocrine Biosciences Inc
- NeuroSolis Inc
- Sosei Group Corp
- Suven Life Sciences Ltd
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Drug Profiles
- (aceclidine + tropicamide) – Drug Profile
- (trospium chloride + xanomeline) – Drug Profile
- blarcamesine hydrochloride – Drug Profile
- emraclidine – Drug Profile
- HTL-0016878 – Drug Profile
- Lead Optimization – Drug Profile
- LS-001 – Drug Profile
- M4 PAMs for Schizophrenia and Other Psychosis – Drug Profile
- ML-007 – Drug Profile
- NMRA-M4R – Drug Profile
- NSX-0527 – Drug Profile
- NSX-0527f – Drug Profile
- NSX-0559 – Drug Profile
- NSX-0559f – Drug Profile
- Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia – Drug Profile
- Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Unspecified Neurologic Diseases – Drug Profile
- Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis – Drug Profile
- VU-0467154 – Drug Profile
- VU-6000918 – Drug Profile
- VU-6001852 – Drug Profile
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Dormant Products
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Discontinued Products
- Muscarinic Acetylcholine Receptor M4 (CHRM4) – Product Development Milestones
- Featured News & Press Releases
- May 18, 2022: Karuna Therapeutics to host virtual event highlighting clinical program for psychosis in Alzheimer’s disease
- Apr 06, 2022: Addex expands pipeline with selective M4 positive allosteric modulator program for the treatment of schizophrenia & other psychotic disorders
- Mar 15, 2022: Anavex Life Sciences announces presentation of phase 2 clinical biomarker data from Anavex 2-73-PDD-001 Parkinson’s disease dementia study at AD/PD™ 2022 International Conference
- Feb 04, 2022: MapLight Therapeutics announces initiation of phase 1 clinical trial for novel therapy to treat patients with schizophrenia or dyskinesias
- Feb 04, 2022: Anavex life sciences provides supplemental information on ANAVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome
- Feb 01, 2022: ANAVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and secondary efficacy endpoints
- Jan 10, 2022: Humanigen Aligns with FDA on potential registration phase 3 study for lenzilumab with CAR-T
- Oct 13, 2021: Anavex Life Sciences reports data review by the independent DSMB reported for phase 2b/3 trial of ANAVEX 2-73 for AD
- Sep 13, 2021: Novamind to serve as research site for Karuna Therapeutics late-stage clinical trial
- Sep 10, 2021: Cerevel Therapeutics to Host Virtual R&D Event on October 7, present update on CVL-231
- Aug 26, 2021: Anavex Life Sciences announces publication of Foundational data for ANAVEX2-73 (blarcamesine) in Fragile X syndrome (Autism)
- Jul 29, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) significantly prevented Aß (Abeta)-induced cognitive deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease
- Jun 29, 2021: Cerevel Therapeutics announces positive topline results for CVL-231 in phase 1b clinical trial in patients with schizophrenia
- Jun 29, 2021: Anavex reports positive data from Parkinson’s disease dementia study
- Jun 23, 2021: Karuna Therapeutics announces results from phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development by Stage of Development, 2022
- Table 2: Number of Products under Development by Therapy Areas, 2022
- Table 3: Number of Products under Development by Indication, 2022
- Table 4: Number of Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Companies, 2022 (Contd..2)
- Table 8: Number of Products by Stage and Mechanism of Actions, 2022
- Table 9: Number of Products by Stage and Route of Administration, 2022
- Table 10: Number of Products by Stage and Molecule Type, 2022
- Table 11: Pipeline by Addex Therapeutics Ltd, 2022
- Table 12: Pipeline by Anavex Life Sciences Corp, 2022
- Table 13: Pipeline by AstraZeneca Plc, 2022
- Table 14: Pipeline by Cerevel Therapeutics Holdings Inc, 2022
- Table 15: Pipeline by Karuna Therapeutics Inc, 2022
- Table 16: Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, 2022
- Table 17: Pipeline by Lenz Therapeutics LLC, 2022
- Table 18: Pipeline by MapLight therapeutics Inc, 2022
- Table 19: Pipeline by Neumora Therapeutics Inc, 2022
- Table 20: Pipeline by Neurocrine Biosciences Inc, 2022
- Table 21: Pipeline by NeuroSolis Inc, 2022
- Table 22: Pipeline by Sosei Group Corp, 2022
- Table 23: Pipeline by Suven Life Sciences Ltd, 2022
- Table 24: Dormant Products, 2022
- Table 25: Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development by Stage of Development, 2022
- Figure 2: Number of Products under Development by Therapy Areas, 2022
- Figure 3: Number of Products under Development by Top 10 Indications, 2022
- Figure 4: Number of Products by Mechanism of Actions, 2022
- Figure 5: Number of Products by Stage and Mechanism of Actions, 2022
- Figure 6: Number of Products by Routes of Administration, 2022
- Figure 7: Number of Products by Stage and Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Routes of Administration, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.